Formatech, Inc. Donates Manufacturing Services to RegeneRx Biopharmaceuticals, Inc. (RGRX) to Produce Experimental Drug for the Treatment of Multiple Sclerosis
4/30/2010 9:08:03 AM
ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech, Inc. announces the selection of RegeneRx Biopharmaceuticals, Inc.’s therapeutic product candidate RGN-352 as the next Fillanthropy™ Program candidate. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in clinical trials.
comments powered by